An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema (NCT06035120)
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema: The CONVERT II Trial
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.
Who can join: Review the eligibility criteria below.
Location: Banner University Medical Center — Phoenix, Arizona
Age range: 40 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- Banner University Medical Center — Phoenix, Arizona
- Saint Francis Hospital and Medical Center (Trinity Health of New England) — Hartford, Connecticut
- Orlando Health — Orlando, Florida
- Northwestern University — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
- OSF Saint Francis Medical Center — Peoria, Illinois
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Brigham Lung Center — Boston, Massachusetts
- Henry Ford Hospital — Detroit, Michigan
- Cleveland VA Northeast — Cleveland, Ohio
- Penn Medicine — Philadelphia, Pennsylvania
- Temple University — Philadelphia, Pennsylvania
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- University of Pittsburgh Medical Center (UPMC) — Pittsburgh, Pennsylvania
- Fort Sanders Regional Medical Center (StatCare) — Knoxville, Tennessee
- University of Texas Southwestern — Dallas, Texas
- Inova Fairfax Hospital — Falls Church, Virginia
- Medical College of Wisconsin (MCW) — Milwaukee, Wisconsin
- Royal Adelaide Hospital — Adelaide, Australia
- Wesley Hospital — Brisbane, Australia
- Macquarie University — Macquarie Park, Australia
- Klinik Floridsdorf — Vienna, Austria
- Rigshospitalet — Copenhagen, Denmark
- CHU Limoges — Limoges, France
- Hopital Bichat-APHP — Paris, France
📞 Contact the Study Coordinator
Phone: (650) 216-0134
Email: ckutzavitch@pulmonx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Emphysema, Pulmonary clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.